A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
Public ClinicalTrials.gov record NCT02059642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a multisite, randomized, double-blind, placebo-controlled, phase 2/3 study of MG01CI (1400 mg daily) for 6 weeks compared with placebo in a 1:1 ratio of 300 adults with ADHD.
Study identification
- NCT ID
- NCT02059642
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 300 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2014 (Type not available)
- Primary completion
- Sep 2014 (Actual)
- Completion
- Sep 2014 (Actual)
- Last update posted
- Mar 28, 2017
2014
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarkis Clinical Trials | Gainesville | Florida | 32607 | — |
| Miami Research | South Miami | Florida | 33173 | — |
| Capstone Clinical Research | Libertyville | Illinois | 60048 | — |
| Psychiatric Associates | Overland Park | Kansas | 66211 | — |
| University Kentucky Psychiatry | Lexington | Kentucky | 40509 | — |
| Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital | Boston | Massachusetts | 21144 | — |
| Rochester Center For Behavioral Medicine | Rochester Hills | Michigan | 48307 | — |
| Behavioral Medicine Center | Troy | Michigan | 48083 | — |
| St. Charles Psychiatric Associates | Saint Charles | Missouri | 63301 | — |
| Center for Psychiatry and Behavioral Medicine | Las Vegas | Nevada | 89128 | — |
| Bioscience Research | Mount Kisco | New York | 10549 | — |
| Duke University | Durham | North Carolina | 27705 | — |
| Richard H Weisler, MD, PA | Raleigh | North Carolina | 27609 | — |
| Sequoia Behavioral Healthcare | Media | Pennsylvania | 19063 | — |
| FutureResearch Trials | Austin | Texas | 78731 | — |
| FutureResearch Trials Dallas, LP | Dallas | Texas | 75231 | — |
| Bayou City Research | Houston | Texas | 77007 | — |
| NeuroScience, Inc. (NSI) | Herndon | Virginia | 20170 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02059642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2017 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02059642 live on ClinicalTrials.gov.